| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | FGF THERAPEUTICS INC. | 10343 OAK RIDGE DR | ZIONSVILLE | IN | 46077-8313 | BOONE | USA | R41AR084025 | Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia | 000 | 1 | NIH | 1/30/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | FGF THERAPEUTICS INC. | 10343 OAK RIDGE DR | ZIONSVILLE | IN | 46077-8313 | BOONE | USA | R41AR084025 | Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia | 002 | 2 | NIH | 6/21/2024 | $231,003 |
| | 2024 | 2023 | FGF THERAPEUTICS INC. | 10343 OAK RIDGE DR | ZIONSVILLE | IN | 46077-8313 | BOONE | USA | R41AR084025 | Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia | 001 | 1 | NIH | 6/19/2024 | -$231,003 |
| | 2024 | 2023 | FGF THERAPEUTICS INC. | 10343 OAK RIDGE DR | ZIONSVILLE | IN | 46077-8313 | BOONE | USA | R41AR084025 | Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia | 000 | 1 | NIH | 10/17/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $301,892 ) |
| | 2023 | 2023 | FGF THERAPEUTICS INC. | 10343 OAK RIDGE DR | ZIONSVILLE | IN | 46077-8313 | BOONE | USA | R41AR084025 | Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia | 000 | 1 | NIH | 9/19/2023 | $301,892 |
|
|
